GOLDSTEIN DOV A MD 4

4 · BioAge Labs, Inc. · Filed Jan 15, 2026

Insider Transaction Report

Form 4

Period: 2026-01-13

BioAge Labs, Inc.BIOA

GOLDSTEIN DOV A MD

Chief Financial Officer

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-01-13$8.39/sh+27,000$226,530→ 49,408 total
Sale
Common Stock
[F1][F2]
2026-01-13$18.43/sh−8,974$165,371→ 40,434 total
Sale
Common Stock
[F1][F3]
2026-01-13$19.45/sh−4,440$86,370→ 35,994 total
Sale
Common Stock
[F1][F4]
2026-01-13$20.54/sh−11,663$239,549→ 24,331 total
Sale
Common Stock
[F1][F5]
2026-01-13$21.08/sh−1,923$40,538→ 22,408 total
Exercise/Conversion
Stock Option (Right to Buy)
[F1][F6]
2026-01-13−27,000→ 92,587 total
Exercise: $8.39Exp: 2034-04-16→ Common Stock (27,000 underlying)

Footnotes (6)

[F1]This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 2, 2024.
[F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.00 to $18.91 per share, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and in footnotes 3 through 5 of this Form 4.
[F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.86 per share, inclusive.
[F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.04 to $21.02 per share, inclusive.
[F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.04 to $21.15 per share, inclusive.
[F6]The option vested or vests as to 1/48th of the total award monthly, with the first tranche vesting on May 17, 2024, and each subsequent tranche vesting on the monthly anniversary thereof, subject to the reporting person's continued service to the Issuer on each vesting date. Additionally, the entire award is exercisable at any time pursuant to an early exercise feature of the option award.

Signature

/s/ Dov A. Goldstein|2026-01-15

Documents

1 file

4
form4-01152026_090117.xmlPrimary